alzheimers-clinical-trial-consortium

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Clinical Trial Consortium (ACTC)</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Multiple sites across the United States</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Clinical Trial Network</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2019 (as ACTC); predecessor ADCS established 1991</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>National Institute on Aging (NIA)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.nia.nih.gov/research/alzheimers-clinical-trials-consortium-act-tcs" target="_blank">nia.nih.gov/actc</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Clinical Trials, Therapeutic Development</td>
</tr>
<tr>
<td class="label">Parent Institution</td>
<td>[NIH - National Institute on Aging](/institutions/nih-nia)</td>
</tr>
</table>

Alzheimer's Clinical Trial Consortium (ACTC)

Overview

The Alzheimer's Clinical Trial Consortium (ACTC) is a national clinical trial network dedicated to accelerating the development of effective treatments for [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and related dementias[@nia]. Funded by the National Institute on Aging (NIA), the ACTC provides the infrastructure, expertise, and coordination necessary to conduct large-scale, multi-site clinical trials efficiently and rigorously.

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Clinical Trial Consortium (ACTC)</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Multiple sites across the United States</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Clinical Trial Network</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2019 (as ACTC); predecessor ADCS established 1991</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>National Institute on Aging (NIA)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.nia.nih.gov/research/alzheimers-clinical-trials-consortium-act-tcs" target="_blank">nia.nih.gov/actc</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Clinical Trials, Therapeutic Development</td>
</tr>
<tr>
<td class="label">Parent Institution</td>
<td>[NIH - National Institute on Aging](/institutions/nih-nia)</td>
</tr>
</table>

Alzheimer's Clinical Trial Consortium (ACTC)

Overview

The Alzheimer's Clinical Trial Consortium (ACTC) is a national clinical trial network dedicated to accelerating the development of effective treatments for [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and related dementias[@nia]. Funded by the National Institute on Aging (NIA), the ACTC provides the infrastructure, expertise, and coordination necessary to conduct large-scale, multi-site clinical trials efficiently and rigorously.

The ACTC represents the next evolution of Alzheimer's clinical research networks, building upon the legacy of the Alzheimer's Disease Cooperative Study (ADCS), which operated from 1991 to 2019. The consortium brings together leading academic medical centers across the United States to create a unified platform for therapeutic development[@alzheimers].

Mission and Objectives

The ACTC's mission is to accelerate the development of effective Alzheimer's disease treatments by:

History

Alzheimer's Disease Cooperative Study (1991-2019)

The ACTC's predecessor, the Alzheimer's Disease Cooperative Study (ADCS), was established in 1991 as a cooperative agreement between the NIA and academic centers across the United States. The ADCS conducted numerous landmark clinical trials in AD, including:

• Vitamin E and Selegiline trial (1997): One of the first large-scale trials for AD
• [Donepezil](/entities/donepezil) (Aricept) studies: Supported regulatory approval
• IVIG trial: Investigated intravenous immunoglobulin
• A4 Trial (Anti-Amyloid Treatment in Asymptomatic AD): Pioneered prevention trials in preclinical AD

Transition to ACTC (2019)

In 2019, the NIA restructured the ADCS into the Alzheimer's Clinical Trial Consortium, expanding the network and updating its governance structure to meet the evolving needs of AD therapeutic development[@acttc].

Structure and Governance

The ACTC is organized as a distributed network with centralized coordination:

Leadership

• Clinical Trials Committee: Sets scientific direction and priorities
• Executive Committee: Oversees operations and governance
• Data Coordinating Center: Manages trial data and analytics

Member Sites

• Alzheimer's Disease Research Centers
• Major university medical centers with neurology departments
• Specialized memory disorders clinics

Research Focus Areas

Therapeutic Modalities

• Disease-modifying therapies: Targeting amyloid, [tau](/proteins/tau), and other pathological proteins
• Symptomatic treatments: Cognitive enhancers, behavioral interventions
• Prevention trials: Interventions in preclinical and prodromal AD
• Repurposing studies: Investigating existing drugs for AD

Trial Design Innovation

• Adaptive trials: Flexible designs that allow modifications
• Basket trials: Molecularly-targeted approaches
• Platform trials: Master protocols for multiple treatments
• Digital endpoints: Remote monitoring and digital biomarkers

Major ACTC Trials

The ACTC has conducted and continues to support numerous clinical trials, including:

Ongoing and Recent Trials

• Leqembi (lecanemab): Phase 3 trials leading to FDA approval
• [Donanemab](/therapeutics/donanemab): Phase 3 TRAILBLAZER-ALZ studies
• Various prevention trials: Trials in cognitively normal individuals with AD biomarkers
• Clarity AD: Leqembi confirmatory trial in early AD
• TRAILBLAZER-ALZ 3: Prevention trial in cognitively normal subjects

Legacy ADCS Trials

• A4 Trial: Anti-amyloid treatment in preclinical AD
• DIAN-TU: Dominantly Inherited Alzheimer's Network Trials
• Generation Studies: Prevention trials in genetic risk populations
• ADCS Azeliragon Trial: Phase 3 study in early AD
• EXERT Trial: Exercise intervention in MCI

Current Research Pipeline

The ACTC maintains a robust pipeline of upcoming trials:

| Phase | Compound | Target | Status |
|-------|----------|--------|--------|
| Phase 3 | Lecanemab | Amyloid-β | Approved |
| Phase 3 | Donanemab | Amyloid-β | Approved |
| Phase 2 | Semorinemab | Tau | Active |
| Phase 1 | Various | Multiple targets | Recruiting |

Impact on Alzheimer's Research

The ACTC has made significant contributions to the field:

Key Achievements

• Lecanemab approval: Contributed to FDA approval of the first disease-modifying therapy for early AD
• Biomarker standardization: Established CSF and PET biomarker protocols used worldwide
• Trial design innovation: Pioneered adaptive and platform trial approaches
• Global impact: Supported trials in over 150 sites across 5 continents

Training and Career Development

ACTC Training Programs

The consortium invests heavily in training the next generation of AD clinical researchers:

• Clinical Trials Fellowship: 2-year program for early-career investigators
• Summer Institute: Intensive training in AD clinical trial methodology
• Mentorship Program: Pairing junior investigators with experienced mentors

Career Outcomes

ACTC trainees have gone on to:

• Lead clinical trials at major academic centers
• Serve as principal investigators in industry-sponsored studies
• Contribute to FDA regulatory reviews
• Direct research programs at non-profit organizations

Collaboration Networks

National Partnerships

• NIH/NIA: Primary funder and strategic partner
• Alzheimer's Association: Research and advocacy collaboration
• ACTC Sites: 35+ academic medical centers nationwide

International Collaborations

• EU-CTI: European Clinical Trials Initiative
• DIAN-TU: Dominantly Inherited Alzheimer's Network
• APOE Consortium: International genetics collaboration

Governance and Leadership

Current Leadership

The ACTC is led by distinguished researchers in the field:

• Principal Investigator: Dr. Ronald C. Petersen (Mayo Clinic)
• Co-Investigators: Leaders from partner institutions
• Scientific Advisory Board: External experts in AD research

Governance Structure

• Executive Committee: Strategic direction and operations
• Data Safety Monitoring Board: Independent trial oversight
• Publication Committee: Scientific output coordination

Future Directions

Emerging Priorities

The ACTC is positioned to lead next-generation AD trials:

Strategic Initiatives

• REACH Initiative: Increasing participation from underrepresented populations
• Global Health: Extending trial networks to low-resource settings
• Data Science: AI/ML for trial optimization

Member Sites and Institutions

The ACTC brings together leading academic medical centers across the United States, each contributing unique expertise and patient populations:

Major Academic Centers

| Site | Location | Special Expertise |
|------|----------|-------------------|
| University of California, San Diego | San Diego, CA | Early-phase trials, biomarker research |
| Massachusetts General Hospital | Boston, MA | Tau imaging, clinical outcomes |
| University of Southern California | Los Angeles, CA | Latino/Hispanic populations, prevention trials |
| Washington University in St. Louis | St. Louis, MO | DIAN-TU, dominantly inherited AD |
| University of Michigan | Ann Arbor, MI | Clinical operations, recruitment |
| University of Kentucky | Lexington, KY | Rural populations, diverse cohorts |
| Emory University | Atlanta, GA | African American populations |
| Stanford University | Palo Alto, CA | Technology-enabled trials, digital biomarkers |
| Cleveland Clinic | Cleveland, OH | Clinical care integration |
| Mount Sinai | New York, NY | Biomarker development, genomics |

Specialized Expertise by Site

• Prevention-focused sites: California Pacific Medical Center, Banner Sun Health Research Institute
• Early AD sites: Multiple sites with expertise in preclinical and prodromal populations
• Diverse population sites: USC, Emory, University of Florida for underrepresented populations

Clinical Trial Operations

Trial Phases Supported

The ACTC supports clinical trials across all phases of development:

Phase 1 Trials

• First-in-human studies
• Dose-escalation studies
• Safety and tolerability assessments
• Pharmacokinetic/pharmacodynamic studies

Phase 2 Trials

• Dose-finding studies
• Preliminary efficacy assessments
• Biomarker validation
• Proof-of-concept studies

Phase 3 Trials

• Pivotal registration trials
• Large-scale efficacy studies
• Comparative effectiveness
• Long-term safety studies

Infrastructure and Resources

The ACTC provides shared infrastructure including:

• ClinicalTrials.gov registration: Standardized trial registration
• EDC systems: Electronic data capture across all sites
• Central laboratory: Standardized biomarker assays
• Imaging core: MRI, PET, CT imaging standardization
• Statistical core: Power calculations, statistical analysis plans

Trial Design Innovation

Adaptive Trial Designs

The ACTC has been at the forefront of implementing adaptive trial designs in AD:

Sample Size Re-estimation

• Interim analyses allowing sample size adjustments
• Predictive probability approaches
• Bayesian adaptive methods

Treatment Arm Selection

• Drop-loser designs eliminating ineffective arms
• Platform trial master protocols
• Multi-arm multi-stage (MAMS) designs

Enrichment Strategies

• Biomarker-based enrichment
• Genetic stratification (APOE, TREM2)
• Cognitive reserve adjustments

Bayesian Approaches

The ACTC has pioneered Bayesian methods in AD trials:

• Bayesian adaptive randomization: More patients receive potentially effective treatments
• Historical data borrowing: Leveraging prior trial information
• Predictive probability: Early termination decisions
• Subgroup treatment effects: Personalized medicine approaches

Digital Health Integration

Recent ACTC trials incorporate digital health technologies:

• Digital cognitive assessments: Cambridge Neuropsychological Test Automated Battery (CANTAB)
• Wearable devices: Activity monitoring, sleep tracking
• Remote monitoring: Digital biomarkers for disease progression
• Telehealth: Virtual visits, remote consent

Biomarker Program

Core Biomarker Types

The ACTC maintains standardized biomarker collection:

CSF Biomarkers

• Amyloid-β (Aβ40, Aβ42)
• Total tau (t-tau)
• Phosphorylated tau (p-tau181, p-tau217)
• Neurofilament light chain (NfL)

Blood Biomarkers

• Plasma Aβ (Aβ40, Aβ42, Aβ42/40 ratio)
• Plasma tau (p-tau181, p-tau217, p-tau231)
• NfL, GFAP
• Emerging multiplex assays

Imaging Biomarkers

• Amyloid PET (Pittsburgh compound B, florbetapir)
• Tau PET (AV-1451, MK-6240)
• Structural MRI (hippocampal volume, cortical thickness)
• FDG-PET (glucose metabolism)

Biomarker Validation

The ACTC has established rigorous validation protocols:

• Assay standardization: Central laboratory processing
• Longitudinal stability: Characterizing within-subject variability
• Clinical validation: Correlation with clinical endpoints
• Regulatory acceptance: FDA/EMA biomarker qualification

Patient Recruitment and Diversity

Recruitment Strategies

The ACTC has implemented innovative recruitment approaches:

Registry-based Recruitment

• Alzheimer's Prevention Registry
• Brain Health Registry
• Local ADRC registries

Community Outreach

• Faith-based partnerships
• Community health centers
• Minority-serving institutions

Digital Recruitment

• Social media campaigns
• Online advertising
• Clinical trial marketplace platforms

Diversity, Equity, and Inclusion

The ACTC has prioritized increasing representation:

Current Demographics

• Caucasian: ~80%
• African American: ~10%
• Hispanic/Latino: ~7%
• Asian: ~3%

Initiatives to Improve Diversity

• LATINOS program: Spanish-language outreach
• AFA partnership: African American engagement
• Site selection: Geographic diversity
• Inclusion criteria: Expanding eligible populations

Regulatory Relationships

FDA Engagement

The ACTC maintains active regulatory relationships:

Pre-IND Meetings

• Regulatory strategy consultation
• Study design feedback
• Biomarker qualification pathways

Type B Meetings

• End-of-phase 2 meetings
• Pre-phase 3 meetings
• Breakthrough therapy designation support

Post-Approval Studies

• Real-world evidence generation
• Label expansion studies
• Registry-based studies

EMA Coordination

• Parallel scientific advice
• Global trial coordination
• Regulatory harmonization efforts

Data Sharing and Open Science

Data Sharing Policies

The ACTC supports open science:

• Qualified researcher access: Controlled access to trial data
• Summary results posting: ClinicalTrials.gov results posting
• Publication of negative results: No publication bias
• Code sharing: Analysis code on GitHub

Consortium-level Data Initiatives

• AMP-AD: Partnership with NIH Accelerating Medicines Partnership
• NIADS: Data sharing across neurodegenerative disease trials
• GAAIN: Global Alzheimer's Association Interactive Network

Training and Career Development

Investigator Training

The ACTC invests in developing the next generation:

Fellowship Programs

• Clinical trial methodology fellowships
• Clinical research methodology degrees
• Sub-specialty training in AD trials

Mentorship Programs

• Junior investigator mentorship
• Protocol development mentorship
• Leadership development

Site Staff Training

• GCP certification requirements
• Protocol-specific training
• Cognitive assessment certification (ADAS-Cog, CDR)
• Biomarker collection training

Funding and Financial Model

Funding Sources

The ACTC receives funding from multiple sources:

| Source | Percentage | Focus |
|--------|------------|-------|
| NIA Grants | ~70% | Core infrastructure, specific trials |
| Industry | ~25% | Pharmaceutical company trials |
| Foundation | ~5% | Prevention trials, special programs |

Cost Structure

• Per-patient costs: $15,000-30,000 depending on complexity
• Site startup: $50,000-150,000 per site
• Central operations: $2-5 million annually
• Phase 3 trial costs: $50-100 million total

Major Scientific Contributions

Landmark ADCS Trials

The ACTC's predecessor conducted numerous pivotal trials:

Recent ACTC Trials

Future Directions

Emerging Priorities

The ACTC is focusing on:

• Combination therapy trials: Multi-target approaches
• Resilience and prevention: Intervention before symptoms
• Precision medicine: Biomarker-guided treatments
• Point-of-care diagnostics: Decentralized trials

Technology Integration

• Digital twins: Computational modeling of disease progression
• AI/ML: Predictive enrollment, outcome prediction
• Remote trials: Home-based assessments
• Continuous monitoring: Digital biomarkers

Statistics

| Metric | Value |
|--------|-------|
| Member Sites | 35-40 |
| Trials Conducted | 50+ |
| Patients Enrolled | 15,000+ |
| Annual Budget | ~$30M |
| Publications/year | 100+ |
| Active Trials | 10+ |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Clinical Trials in AD](/therapeutics/promising-clinical-trials-neurodegeneration)
• [NIH - National Institute on Aging](/institutions/nih-nia)
• [Alzheimer's Disease Research Centers](/institutions/alzheimers-disease-research-centers)
• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [APOE Gene](/genes/apoe)

References